Does the media refer more to BBIO or LEGN?

In the previous week, Legend Biotech had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Legend Biotech and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Legend Biotech's score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HALO or LEGN?

In the previous week, Legend Biotech had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 7 mentions for Legend Biotech and 6 mentions for Halozyme Therapeutics. Legend Biotech's average media sentiment score of 0.33 beat Halozyme Therapeutics' score of 0.19 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LEGN or BMRN?

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 7 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Legend Biotech's score of 0.33 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LEGN or MDGL?

In the previous week, Legend Biotech had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Legend Biotech's score of 0.33 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LEGN or KRYS?

In the previous week, Legend Biotech had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Krystal Biotech. Legend Biotech's average media sentiment score of 0.33 beat Krystal Biotech's score of 0.25 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Legend Biotech (LEGN) Competitors

$18.57 -0.75 (-3.88%)

Closing price 04:00 PM Eastern

Extended Trading

$18.86 +0.29 (+1.55%)

As of 07:56 PM Eastern

Compare

LEGN vs. BBIO, HALO, BMRN, MDGL, and KRYS

Should you buy Legend Biotech stock or one of its competitors? Legend Biotech's main competitors and comparable companies include BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), and Krystal Biotech (KRYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Legend Biotech compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Legend Biotech has a net margin of -7.21% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Legend Biotech	-7.21%	-8.71%	-5.40%

In the previous week, Legend Biotech had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Legend Biotech and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Legend Biotech's score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma presently has a consensus target price of $102.61, indicating a potential upside of 52.09%. Legend Biotech has a consensus target price of $55.79, indicating a potential upside of 197.84%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.27	-$724.93M	-$3.57	N/A
Legend Biotech	$1.03B	3.53	-$296.80M	-$0.25	N/A

Summary

BridgeBio Pharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Halozyme Therapeutics has a net margin of 24.86% compared to Legend Biotech's net margin of -7.21%. Halozyme Therapeutics' return on equity of 260.98% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Legend Biotech	-7.21%	-8.71%	-5.40%

Halozyme Therapeutics has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.88	$316.89M	$3.35	32.60
Legend Biotech	$1.03B	3.53	-$296.80M	-$0.25	N/A

Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 16.50%. Legend Biotech has a consensus target price of $55.79, suggesting a potential upside of 197.84%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

In the previous week, Legend Biotech had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 7 mentions for Legend Biotech and 6 mentions for Halozyme Therapeutics. Legend Biotech's average media sentiment score of 0.33 beat Halozyme Therapeutics' score of 0.19 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Legend Biotech on 12 of the 15 factors compared between the two stocks.

How does Legend Biotech compare to BioMarin Pharmaceutical?

Legend Biotech (NASDAQ:LEGN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

BioMarin Pharmaceutical has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.53	-$296.80M	-$0.25	N/A
BioMarin Pharmaceutical	$3.22B	3.48	$348.90M	$0.37	156.45

Legend Biotech presently has a consensus target price of $55.79, suggesting a potential upside of 197.84%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 54.05%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 7 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Legend Biotech's score of 0.33 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Legend Biotech's net margin of -7.21%. BioMarin Pharmaceutical's return on equity of 5.32% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Legend Biotech on 14 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Legend Biotech (NASDAQ:LEGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Legend Biotech had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Legend Biotech's score of 0.33 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Legend Biotech has a net margin of -7.21% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Legend Biotech's return on equity of -8.71% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.53	-$296.80M	-$0.25	N/A
Madrigal Pharmaceuticals	$958.40M	11.96	-$288.28M	-$12.89	N/A

Legend Biotech presently has a consensus price target of $55.79, indicating a potential upside of 197.84%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 43.16%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Legend Biotech and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Krystal Biotech?

Legend Biotech (NASDAQ:LEGN) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Legend Biotech currently has a consensus target price of $55.79, indicating a potential upside of 197.84%. Krystal Biotech has a consensus target price of $377.20, indicating a potential upside of 16.40%. Given Legend Biotech's higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Legend Biotech had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Krystal Biotech. Legend Biotech's average media sentiment score of 0.33 beat Krystal Biotech's score of 0.25 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.53	-$296.80M	-$0.25	N/A
Krystal Biotech	$389.13M	24.65	$204.83M	$7.98	40.61

Legend Biotech has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Legend Biotech's net margin of -7.21%. Krystal Biotech's return on equity of 19.34% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats Legend Biotech on 12 of the 17 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.74B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-74.28	7.65	214.49	21.54
Price / Sales	3.50	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.42	16.63	10.92	6.30
Net Income	-$296.80M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-2.83%	-3.05%	-2.11%	-1.67%
1 Month Performance	-15.17%	-10.75%	-6.34%	-3.94%
1 Year Performance	-42.49%	21.11%	8.81%	2.77%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	3.5538 of 5 stars	$18.57 -3.9%	$55.79 +200.4%	-40.8%	$3.74B	$1.03B	N/A	2,965	Insider Trade
BBIO BridgeBio Pharma	3.0956 of 5 stars	$66.58 0.0%	$102.61 +54.1%	+25.1%	$13.02B	$502.08M	N/A	839
HALO Halozyme Therapeutics	2.7512 of 5 stars	$111.45 -0.9%	$91.20 -18.2%	+42.7%	$12.76B	$1.40B	33.27	423	Insider Trade
BMRN BioMarin Pharmaceutical	4.4621 of 5 stars	$64.06 +0.2%	$89.17 +39.2%	+6.5%	$12.38B	$3.22B	173.14	3,221	Trending News
MDGL Madrigal Pharmaceuticals	3.0007 of 5 stars	$521.96 -1.8%	$699.64 +34.0%	+11.3%	$12.28B	$958.40M	N/A	915

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, HALO, BMRN, MDGL, and KRYS

How does Legend Biotech compare to BridgeBio Pharma?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Summary

How does Legend Biotech compare to BioMarin Pharmaceutical?

Summary

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Summary

How does Legend Biotech compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, HALO, BMRN, MDGL, and KRYS

How does Legend Biotech compare to BridgeBio Pharma?

Do insiders and institutionals believe in BBIO or LEGN?

Which has more risk and volatility, BBIO or LEGN?

Is BBIO or LEGN more profitable?

Does the media refer more to BBIO or LEGN?

Do analysts recommend BBIO or LEGN?

Which has stronger valuation & earnings, BBIO or LEGN?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Is HALO or LEGN more profitable?

Which has preferable valuation & earnings, HALO or LEGN?

Which has more volatility & risk, HALO or LEGN?

Do analysts recommend HALO or LEGN?

Does the media refer more to HALO or LEGN?

Do insiders & institutionals have more ownership in HALO or LEGN?

Summary

How does Legend Biotech compare to BioMarin Pharmaceutical?

Which has better earnings & valuation, LEGN or BMRN?

Do analysts rate LEGN or BMRN?

Does the media favor LEGN or BMRN?

Which has more risk & volatility, LEGN or BMRN?

Do institutionals and insiders believe in LEGN or BMRN?

Is LEGN or BMRN more profitable?

Summary

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Does the media favor LEGN or MDGL?

Which has more risk & volatility, LEGN or MDGL?

Do insiders & institutionals have more ownership in LEGN or MDGL?

Is LEGN or MDGL more profitable?

Which has higher earnings and valuation, LEGN or MDGL?

Do analysts prefer LEGN or MDGL?

Summary

How does Legend Biotech compare to Krystal Biotech?

Do analysts prefer LEGN or KRYS?

Do institutionals and insiders have more ownership in LEGN or KRYS?

Does the media favor LEGN or KRYS?

Which has preferable valuation and earnings, LEGN or KRYS?

Which has more volatility & risk, LEGN or KRYS?

Is LEGN or KRYS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools